Q32 bounces back to claim study success for alopecia drug
Q32 bounces back to claim study success for alopecia drug
Q32 Bio
Q32 Bio is a clinical-stage biotechnology company developing therapeutics targeting the IL-7 / TSLP pathways for autoimmune and inflammatory diseases. Lead candidate bempikibart (ADX-914) is an anti-IL-7R antibody in Phase 2 development for alopecia areata. The company was formed from the merger of Q32 Bio and Homology Medicines in 2024.
Company Info
Sector:Immunology / Autoimmune disease
Headquarters:Waltham, Massachusetts, USA
Founded:2017
Website:www.q32bio.com
Recent News
Q32’s stock jumps 60% on latest phase 2 alopecia data
The latest phase 2 readout for Q32 Bio’s alopecia hopeful received a warm reception from investors, backing up the biotech’s claim that the drug could offer a more durable alternative to JAK inhibitors. The data, released Monday morning, come from part B of the Signal-AA study, which enrolled 33 patients with severe or very severe alopecia areata to receive the anti-IL-7R antibody bempikibart. Patients received a 200-mg subcutaneous dose weekly for four weeks, followed by 200 mg every other week
Leadership Team
TBD
CEO
Careers & Job Openings